Cardiovascular

Don’t use Promacta for patients with chronic liver disease

On May 2, the U.S. Food and Drug Administration and GlaxoSmithKline reminded health professionals not to use Promacta (eltromobopag) for the treatment of thrombocytopenia in patients with chronic liver disease. Read more at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm211796.htm.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares